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THE FATE OF GENE PATENTS UNDER THE NEW UTILITY GUIDELINES
¶ 1           The United States Patent and Trademark Office (PTO) recently finalized its patent
utility guidelines.1 Promulgated by the PTO, the new guidelines will be used by patent
examiners in determining whether a claimed invention should be awarded patent protection2 and
will be used by patent applicants and attorneys who file patent applications. The guidelines
focus primarily on the utility standards for gene and gene fragment patents, an issue that was
featured in the PTO's 1999 Revised Interim Utility Guidelines3 and has been the subject of
considerable public debate.
¶ 2           The patenting of genetic sequences implicates a number of policy issues, ranging from
individual privacy concerns to controversies over who should control the use of DNA sequences.
In promulgating the new guidelines, however, the PTO predictably focused more on technical
issues than on these larger policy issues. For instance, the PTO considered (and largely rejected)
technical arguments supporting an overall prohibition on gene patents. These arguments
included contentions that (1) the process of discovering genes is merely an obvious extension of
already available technology,4 and (2) an inventor should not be given a patent when he
discloses only a single useful function for a particular gene.5 While these arguments primarily
focused on technical reasons for the exclusion of gene patents--i.e., reasons having to do with
novelty, utility, and non-obviousness--their rejection by the PTO may have been based on larger
policy concerns.
¶ 3           The utility of gene fragments presents particular problems. The use of DNA pieces as 
molecular probes is perhaps the most controversial issue addressed by the new guidelines. 
Proponents of gene patents argue that even gene fragments, pieces of DNA also known as 
express sequence tags (ESTs),6 should be patentable because these fragments are regularly used 
as molecular probes to search for complete genes.7 Others argue that ESTs should be 
unpatentable as long as their utility is limited to research--that is, before the final physiological 
function of the EST is discovered. The new guidelines attempt to resolve these competing 
positions by upholding the general concept that genes can be patented, but raising the utility bar 
for the patenting of gene fragments. Although the PTO's position that some ESTs can be 
patented thus strikes a balance in terms of policy, the technical framework chosen by the PTO
leaves a number of questions unresolved.
¶ 4           This iBrief first describes the backdrop of the Utility Examination Guidelines. It then
explains the PTO's standard for determining utility of genetic material, as set out in the 1999
Revised Interim Utility Guidelines and the newly-released final guidelines. Finally, this iBrief
critically analyzes the final guidelines as they pertain to gene patents.8
Background: The Gene Patent Controversy
¶ 5           The controversy over gene patents emerged when Dr. Craig Vetner, CEO of Celera
Genomics, sent 20,000 gene sequences to the PTO, claiming patents to the sequences and to
procedures that would be used to diagnose disorders with the genes. The PTO denied these
applications, suggesting that simply finding DNA sequences and claiming their use as a research
reagent was not sufficient for a patent. The PTO thus indicated that it required the inventor of a
gene to show a level of utility beyond the gene's use as a research tool.
¶ 6           The standard of utility wielded by the PTO, however, has been far from clear. For
example, the PTO recently issued a patent to Human Genome Sciences (HGS) in Rockville,
Maryland claiming the gene for CCR5, a receptor that binds protein molecules termed
"chemokines" at the surface of CD4+ leukocyte cells.9 HGS was issued a patent on the CCR5
gene, its protein, and fragments of DNA for locating the gene. But the patent does not disclose
the function of the particular claimed protein. The specification discloses the chemical building
blocks that made up the gene and its protein, information that was deduced by homology studies
between the new CCR5 and known chemokine receptors and G-proteins. The specification also
discloses a wide variety of uses for known chemokines, including inflammation, immune
reactions, allergies, and arthritis.10 The specification further discloses a number of biological
functions for known G-proteins, including dopamine receptors, protein kinases, and adenylate
cyclase.11 Yet, significantly, the specification does not disclose the function of this particular
protein.
¶ 7           Such function was later published in 1996 by independent researchers at the National
Institutes of Health (NIH), who reported that CCR5 works as a co-receptor in binding
HIV.12 Having performed the necessary research to identify the co-receptor's function, NIH
contended that it was their group, rather than HGS, that made the "discovery."13 But HGS was
issued the patent, despite not being the first group to identify the gene's role in HIV and not
doing any of the research to show that role. The net effect, of course, is that HGS can now
exclude other groups, including the NIH group, from using the gene in HIV treatment.
¶ 8           As the example of the CCR5 patent indicates, the PTO's standard for gene utility has
been unevenly applied. In 1995, the PTO established "Utility Examination Guidelines" for
training its examiners to review biotechnology patent applications in an attempt to bring clarity
to the standard.14 Under the 1995 standard, an invention that had a "credible" utility could be
patented. If not credible, then the invention could still be patented if it had a "well-established"
utility. Under this standard, examiners began to more freely issue patents that covered genetic
material.15 But this practice was criticized extensively, and in 1999 the PTO issued its Revised
Interim Utility Guidelines16 with the intent of tightening the standard and restricting the
issuance of gene patents.17
The Rise of 2001 Utility Examination Guidelines
¶ 9           The key issue in patenting genetic material has always revolved around the utility of
the claimed genes and fragments. The 1999 Revised Interim Utility Guidelines established a
heightened standard for utility, at least under the "credible utility" test. Under the 1999 standard,
"credible utility" was not sufficient without an additional showing of "specific" and "substantial"
utility. The policy of this heightened standard was based on the PTO's adoption of the US
Supreme Court's position in Brenner v. Manson that a patent is not given as a reward for the
search of an invention's utility but, rather, a reward for actually discovering that utility.18
¶ 10           Accordingly, the 1999 Revised Interim Utility Guidelines retained the structure of
two different tests for utility, either of which, if satisfied, was sufficient for a showing of
statutory utility. The first test under the 1999 guidelines was, like the 1995 standards, whether or
not the invention had a "well-established utility."19 Yet the 1999 standards differed from the
1995 standards in that a "credible" utility was no longer sufficient by itself. If the invention did
not have a well-established utility, the second test was applied, namely whether the invention
had a utility that was "specific," "substantial," and "credible."20
¶ 11           In response to comments, the PTO issued its final version of the utility guidelines in
January 2001.21 The 2001 Utility Examination Guidelines follow the 1999 Revised Interim
Utility Guidelines in adopting the structure of two alternative tests for showing utility. These
two tests are the "specific, substantial, and credible" utility test and the "well-established utility"
test.
The "Specific, Substantial, and Credible" Utility Test
¶ 12           The definitions of "specific, substantial, and credible" under the new guidelines are
the same as those described in the 1999 Revised Interim Utility Guidelines' Training Materials
issued to patent examiners. Under both the 1999 and 2001 guidelines, a utility is "specific" when
it is particular to the subject matter claimed.22 For example, a fragment of nucleic acid that has a
claimed utility as a gene probe or chromosome marker would not pass the "specific utility"
hurdle without also identifying the particular gene or chromosome target.23 Unless it discloses
its target, the fragment is no more useful than any random fragment of nucleic acid.24 Similarly,
stating that a gene is useful as "a diagnostic" is ordinarily not sufficiently specific without also
identifying the condition that is diagnosed.25
¶ 13           In addition, both the 1999 and 2001 guidelines establish that a "substantial utility" is
one that defines a "real world" use.26 The PTO's test for determining "real world" use is whether
further research is required to identify an immediate benefit.27 For example, a nucleic acid does
not have a substantial utility if it is only useful for studying its own properties. By contrast, a
nucleic acid used to identify genes that have a known link to a specific disease would satisfy the
"real world" use requirement, even if a cure for the disease does not become available for many
years. The "real world" requirement is designed to prevent the granting of patents if further
research must be performed before the genetic material can be used for a specific purpose or
benefit.28 This rule derives from the US Supreme Court's position in Brenner that a chemical or
a chemical process is not sufficiently useful if its only use is as an object of scientific research.29
¶ 14           The 2001 guidelines also adopt the PTO's past position that any asserted utility must
be a "credible" utility, a standard determined by whether a person with ordinary skill in the art
would accept that the invention "is currently available for such use."30 Such a standard is
presumptively satisfied unless the logic underlying the assertion is seriously flawed, or if the
facts upon which the assertion is based are inconsistent with the logic underlying the
assertion.31 For instance, a nucleic acid used as a probe for a particular gene would likely satisfy
the credibility requirement because nucleic acids are commonly used as probes.32
The "Well-Established Utility" Test
¶ 15           While the 2001 Utility Examination Guidelines essentially adopt the "specific, 
substantial, and credible" test from the 1999 Revised Interim Utility Guidelines, the same is not 
entirely true for the "well-established utility" test.33 Importantly, the "well-established utility" 
test has now been expanded to incorporate the "specific, substantial, and credible" standard. In 
other words, although the new guidelines theoretically still employ two separate, alternative
tests, in reality an applicant seeking to qualify under just the "well-established utility" test must
now satisfy the "specific, substantial, and credible" standard as well.
¶ 16           Under the 1999 guidelines, gene fragments were evaluated based on the "specific,
substantial, and credible" test because, as noted by Stephan Kunin of the PTO, "at the present
time, there is no well-established utility for these fragments."34 The distinction between a
"well-established utility" and a utility that is not "well-established" was ambiguous under the
1999 guidelines. This ambiguity is seen in the PTO's suggestion that a protein that limits the
production of a second protein of well-known identity was sufficiently
"well-established,"35 while a protein used to identify a second protein of not-so-well known
identity was not sufficiently "well-established."36 The critical feature apparently was not the
new protein's function as a locator, but whether the located product had been known for a while.
¶ 17           Despite the PTO's position that gene fragments are not patentable if useful only as
probes, the 1999 version did not entirely foreclose the possibility that fragments might, over
time, develop the status of possessing "well-established utility" and thereby qualify as patentable
inventions. This possibility is foreclosed, however, because the 2001 guidelines formally import
the "specific, substantial, and credible" test into the test for a "well-established utility."37 Thus,
under the 2001 guidelines, any patent claim to a gene fragment must satisfy the "specific,
substantial, and credible" test in order to establish utility under any circumstances.
Ambiguities in the New Guidelines
¶ 18           As described above, there is an essential tension between those who believe that
genes (and gene fragments) are patentable if they have research utility, and those who argue that
genes are not patentable until their final physiological function is discovered. This is not just a
technical issue; it is also a policy issue. If the PTO allows any sort of utility to meet the standard
for patentability, it could result in an influx of gene patents that would ultimately stifle genetic
research. On the other hand, setting the utility hurdle too high could create insufficient incentive
for scientists who rely on patents to create funding for further research.
¶ 19           The new guidelines attempt to resolve this tension by requiring that any application
for a gene patent show that the gene's utility is "specific, substantial, and credible." The PTO's
heightened utility policy for gene patents aims to ensure that genes can be patented, but not
before their physiological use is discovered. Despite the worthiness of this compromise,
however, the framework chosen by the PTO is not airtight, leaving a number of questions
unresolved.
Why Can't ESTs Become "Well-Established" as Probes?
¶ 20           The new guidelines adopt the position that the genetic sequences known as ESTs are
not of sufficiently "well-established" utility if they are only useful as probes, chromosome
markers, or other research tools. Under the new guidelines, ESTs can never have a
well-established utility because, by definition, they do not satisfy the specific and substantial
utility tests.
¶ 21           Yet, the conceptual difference between a "well-established" utility and a not
"well-established" utility under the 1999 guidelines was more a matter of how long the use has
been known than the relative level of public benefit derived from the use.38 ESTs are used as
tools in genetic research because they bind to and identify longer pieces of DNA,39 a process
that has become important to the biotechnology industry over the past few years as a primary
means of identifying and characterizing DNA. ESTs can be used as probes whether they
ultimately find a target or not, unlike chemicals whose only utility depends upon the actual
exhibition of biological activity.40 Furthermore, a probe that successfully locates a gene that
codes for a specific protein has performed its task, regardless of how the protein functions in a
living system.
¶ 22           Accordingly, the PTO has acknowledged that ESTs can pass as "credible" inventions
because "those skilled in the art recognize that [ESTs] could potentially have utility in a variety
of credible contexts, e.g., as probes, chromosome markers, diagnostic tools, and forensic
tools."41 Why this recognized use of ESTs to locate genes could not eventually lead to a finding
of well-established utility is not immediately clear under the new guidelines.
Why are EST Probes Not of "Specific" Utility?
¶ 23           Another problem in the new guidelines is the requirement of specific utility. When
evaluating an asserted utility, the PTO will ask whether that utility is common to any member of
a general class.42 If so, then the asserted utility is not "specific" enough, as may be seen where
the asserted utility of a newly discovered protein is its use as a source of amino acid nutrients.
The new guidelines, however, do not articulate why inventions useful mainly as discovery tools
(for instance using ESTs as gene probes) are not considered to have "specific utility."43
¶ 24           Indeed, while it is true that any gene can be fashioned into a probe, not all probes can 
successfully locate any given gene. A probe is, by its definition, specific to a limited number of 
genes. Thus, the PTO's position that the use of ESTs as probes is not of "specific utility" appears
inconsistent with its rationale.
Why are EST Probes Not of Substantial Utility?
¶ 25           Finally, the new guidelines do not appear to take into account case law governing the
standard for substantial utility. One argument the PTO uses against allowing probes to be
patented is that an invention must have more substantial utility than merely for use in further
experiment upon itself. This argument was enunciated in Brenner v. Manson and re-stated in
subsequent federal circuit cases. The Brenner Court stated emphatically that an invention was
not patentable if its only use was that it might be an "object of scientific research."44 The Court
of Customs and Patent Appeals applied the language from Brenner and disallowed patents that
claimed compounds used in intermediate processes of making final compounds where the utility
of the final compounds was not known.45 By implementing this language in the 2001
Guidelines, the PTO significantly eliminates applications where the claimed utility is only that
the invention can be used for further study of its own utility (presumably such further study
would be used to determine any other uses of the invention).
¶ 26           Yet the PTO has not recognized that patents have been granted for products with
anti-tumor effectiveness demonstrated only in laboratory animals--where the animals themselves
were mere objects of scientific research.46 Other cases have similarly found sufficient utility
even where the invention could not readily be used by anyone.47 Indeed, many compounds
demonstrated only by animal testing to be useful are not immediately beneficial to humans as
espoused by the guidelines.48 Therapeutics and other inventions with uses established solely
through animal studies are patentable because they will "marshal resources and direct the
expenditure of effort to further in vivo testing of the most potent compounds, thereby providing
an immediate benefit to the public."49 This effect--the inspiring of in vitro testing--is precisely
one of the effects of allowing a patent on an EST probe.
¶ 27           Furthermore, a long held pre-Brenner case law standard supports judging the utility
of an invention on whether or not the public derives a benefit from the invention, regardless of
how slight the benefit.50 DNA fragments are widely used as probes, markers, and diagnostics in
the biotechnology industry, playing key roles in drug and disease discovery processes. Indeed,
these fragments enable researchers to find the genes associated with physiological functions.
The discovery of such functions readily benefits the public. Accordingly, such tools could
satisfy the pre-Brenner case law standard.
What Utility Should an Applicant Disclose?
¶ 28           Despite these ambiguities in the tighter standard for EST patents, an applicant can
successfully gain a patent on an EST if he can satisfy the "specific, substantial, and credible
utility" test. This test was derived from federal circuit precedent51 with the intent to ensure that
all patents have "real world" utility52 and to limit the extension of patents involving molecules
with utility that is applicable to any member of that molecule's class.53 Accordingly, an
applicant for a gene fragment patent must disclose more than the DNA sequence of the
fragment, more than the sequence of the complete gene, and more than the size of the protein
product that comes from the gene.
¶ 29           Such additional information should probably include54 a particular biological
reaction involving the protein product,55 or it might include a disease or other cellular
mechanism to which the complete gene is correlated.56 Alternatively, an EST may be patentable
if its gene is shown to be homologous to a gene in another species.57 Furthermore, even if the
gene product itself is not known, a claimed DNA fragment that "hybridizes near a
disease-associated gene or has a gene-regulating activity" may have sufficient
utility.58 However, if the sole utility stated or implied for the claimed EST is for use in locating
a full gene, protein, or some other molecular target, utility will likely not be sufficient absent
knowledge of the physiological process of the target molecule.59
¶ 30           But the decision of what utility to disclose is complicated in at least three ways. First,
no training materials have yet been published with the 2001 Utility Examination Guidelines.
Presumably, the 1999 Revised Interim Utility Guidelines' Training Materials will be used by
patent examiners until new materials are issued, but whether revised training materials will
differ from the existing training materials is not yet clear.
¶ 31           Second, applicants should be aware that the 1999 Training Materials and other
writings by the PTO have been interpreted to leave significant discretion to the PTO to evaluate
utility. One of the PTO's primary threshold questions is, of course, whether or not the asserted
utility requires "additional knowledge" before the invention can be practiced. Under this
principle, at least one member of the PTO has interpreted the new guidelines to authorize the
rejection of an EST patent for lacking a wide range of information, including the following:60
• the sequence of the corresponding complete mRNA sequence, protein coding sequence or
genomic sequence;
• whether there are sequence polymorphisms linked to the corresponding genomic location;
• the function of the protein encoded by the corresponding mRNA;
• the phenotype of a mutation in the corresponding gene;
• the tissue distribution of the corresponding mRNA and tissue-specific expression levels;
• the map location of its corresponding genomic sequence.
¶ 32           Any of the above could be very difficult to determine for a given EST. Yet, not
knowing the complete mRNA sequence of the EST certainly does not preclude the inventor from
identifying the protein product, nor does it prevent the inventor from discovering the
physiological role of the protein.
¶ 33           Third, the new guidelines do not clearly articulate, nor do the 1999 Training
Materials suggest, a standard for how closely an EST must correlate with a particular
physiological condition. In other words, the line between speculation and genuine correlation is
not entirely clear. As noted previously, the CCR5 patent discloses the chemical building blocks
of the new gene and protein, yet the disclosure does not demonstrate a particular function for the
particular protein. Rather, the specification assumes by homology studies that the new CCR5 is,
at first, a G-protein and, second, that it will bind chemokines. If such is the activity, then a
variety of diseases would be implicated, including cancer, blood disorders, allergies, and
arthritis.
¶ 34           The PTO was urged during the last comment period to include an anti-speculation
standard in the Guidelines that would limit gene or gene fragment patent coverage to the specific
uses actually disclosed in the application.61 The PTO refused to adopt such a standard, noting
that the concept is inconsistent with the patent statute's provision that only one utility need be
shown to warrant a patent for an invention.62 Thus, in adhering to the integrity of US patent law,
the PTO has shifted the question back to Congress for a standard as to speculative and
non-speculative utilities. Until that standard is clarified, patent applicants will likely have
considerable leeway in proposing possible utilities of genes and proteins. Given that the
incentive for inventors is to speculate widely as to the utility of claimed genes, fragments, and
proteins, the increased number of patent applications for genetic material could force the PTO to
clarify its position.
Conclusion
¶ 35           Although the debate over whether genetic material should be patentable may not be 
resolved any time soon, the 2001 Utility Examination Guidelines tend to reinforce the PTO's 
disfavor of granting patents for genes and fragments of unknown utility. Nevertheless, the lack
of clarity and uniformity in the new guidelines suggest that, while the PTO's stricter utility
standards may serve its policy goal of limiting (but not eliminating) gene patents, loopholes exist
with respect to technically demonstrating the utility of genetic materials. If the PTO issues new
training materials, these may help resolve questions as to what evidence inventors should
disclose when applying for gene patents. For now, applicants should consider disclosing a
particular physiological process or clinical condition that may be implicated by the gene's
protein product. Such information will likely establish sufficient "specific, substantial, and
credible" utility for not only the protein, but also for its corresponding gene and the EST used to
locate the gene.
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